2m 2m 2m 2m 2m 2m 2m
- $654.6MMarket Cap
- 28.62%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Phibro Animal-A (PAHC)
Key Performance
More- Earnings Score: 74
- Momentum Score: 60
- True Yield: N/A
- Financial Health Score: 94
Latest Research & News
Phibro's CEO transition puts this insider sale in context
Jack Bendheim, CEO of Phibro Animal Health Corporation, sold 18,608 shares worth $1 million through a pre-scheduled trading plan adopted in December 2025, coinciding with his transition to Executive Chairman as his son Daniel takes over as CEO on July 1, 2026. Despite the sale reducing his indirect holdings by about 25%, Bendheim maintains significant ownership. Analysts view this as a natural wind-down for a long-tenured executive rather than a bearish signal, with focus shifting to the new CEO's ability to integrate Zoetis's medicated feed additive portfolio and maintain margin expansion.
05/23/2026, 5:07 PM • The Motley Fool
Phibro Animal Health President and CEO Sells 72k Shares After Strong Q2 2026 Performance
Jack Bendheim, President and CEO of Phibro Animal Health Corporation, sold 72,198 shares indirectly for approximately $3.74 million between February 10-11, 2026, under a pre-existing Rule 10b5-1 trading plan. The sale occurred following strong Q2 2026 earnings with year-over-year growth in revenue, net income, and EPS. The company's medicated feed additive portfolio has grown faster than expected, particularly following its late 2024 acquisition of over 37 product lines.
02/22/2026, 2:08 AM • The Motley Fool
The global glycolic acid market is projected to grow at a CAGR of 5.73% from 2026 to 2032, reaching USD 461.74 Million by 2032, up from USD 295.68 Million in 2024. Growth is driven by increasing demand in personal care, pharmaceuticals, and industrial cleaning applications, though regulatory challenges and raw material price volatility pose restraints.
01/13/2026, 10:45 PM • GlobeNewswire
Phibro Animal Health Q4 Revenue Up 39%
Phibro Animal Health reported strong Q4 FY2025 earnings, with 39% revenue growth driven by the Zoetis medicated feed additive acquisition. Despite robust sales and adjusted EBITDA, gross margins declined due to higher distribution costs and product mix challenges.
08/27/2025, 5:22 PM • The Motley Fool
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
Key Executives
- Jack Clifford Bendheim
- Larry L. Miller
- Glenn C. David
- Daniel Bendheim
- Judith A. Weinstein
Current Ownership Distribution
- Institutions376.0M (72.87%)
- Mutual Funds117.3M (22.74%)
- Insiders22.6M (4.39%)
- Other0 (0.00%)